Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
where to buy fat dildos? - LovToyLand.com
Popular Articles

Queensland Government Funds Univeristy Of Queensland Cancer Fight
University of Queensland (UQ) researchers will use a $5 million grant from the Queensland State Government to unlock the genetic causes of pancreatic and ovarian cancer.
diet pills
Enzyme Doesn't Act Alone In Atrial Fibrillation
An overactive enzyme is behind a leaky calcium channel that plays a role in the development of atrial fibrillation, which is the most common cardiac arrhythmia that is responsible for a third of all strokes. However, it doesn"t act alone, say researchers at Baylor College of Medicine. The findings can be found online in the current edition of the Journal of Clinical Investigation.
News of the day
Based On New Study, Tobacco Control Researchers Call On FDA To Require Complete Disclosure From Tobacco Companies Of Changes Made To Cigarettes
As President Obama prepares to sign a bill giving the Food and Drug Administration (FDA) oversight of the tobacco industry, a new study from Harvard School of Public Health (HSPH) researchers shows that tobacco manufacturers have continually changed the ingredients and the design of their cigarettes over time, even if those changes have exceeded acceptable product variance guidelines. The result, say the researchers, is that consumers who buy the same brand of product are not made aware of how that product has been altered and what effect those alterations might have on their levels of addiction or harm.
Endocrinology

Halozyme Begins Phase 2 Clinical Trial Of Insulin-PH20 In Type 2 Diabetic Patients

Halozyme Therapeutics, Inc. (Nasdaq:HALO) today announced the commencement of patient dosing in a Phase 2 clinical study of Insulin-PH20 in patients with Type 2 Diabetes Mellitus. This randomized cross-over design study is designed to compare the postprandial glycemic excursions following a standardized test meal after treatment with either insulin lispro+PH20 or regular insulin+PH20 relative to treatment with lispro (Humalog) alone. "This study is designed to confirm in type 2 diabetes patients the benefit of reduced postprandial hyperglycemia observed in a previous Phase 2 study conducted in type 1 diabetes patients for which interim results were reported earlier this year," explained Douglas Muchmore, M.D., Halozyme"s vice president of clinical development for endocrinology. "Unlike the previous study where identical doses of lispro were given with and without PH20 to facilitate a direct pharmacokinetic comparison, the doses of each of the three drugs will be titrated independently in this study to directly compare the glycemic response under optimum treatment conditions." This Phase 2 study will investigate the pharmacokinetics (PK) and glucodynamics of insulin lispro+PH20 and regular insulin+PH20 versus lispro alone. The primary endpoint of this study is the glycemic excursion over the first 4 hours. Secondary endpoints include the comparison of optimum doses of insulin required for glycemic control, as well as various PK, PD and safety endpoints. A number of clinical trials investigating Halozyme"s Insulin-PH20 are currently underway and more trials are planned. Halozyme Therapeutics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009